Melvin Munsaka

502 total citations
14 papers, 301 citations indexed

About

Melvin Munsaka is a scholar working on Oncology, Toxicology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Melvin Munsaka has authored 14 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 3 papers in Toxicology and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Melvin Munsaka's work include Pharmacovigilance and Adverse Drug Reactions (3 papers), Diabetes Treatment and Management (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Melvin Munsaka is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (3 papers), Diabetes Treatment and Management (3 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Melvin Munsaka collaborates with scholars based in United States, United Kingdom and Germany. Melvin Munsaka's co-authors include P. Fleck, Venu Menon, Michie Hisada, Candy Wilson, Richard E. Pratley, William B. White, Aziz Karim, Takashi Ohira, Paul B. Watkins and John Marcinak and has published in prestigious journals such as The American Journal of Gastroenterology, SLEEP and Epilepsia.

In The Last Decade

Melvin Munsaka

13 papers receiving 290 citations

Peers

Melvin Munsaka
S. Aubrey Stoch United States
Tine Laethem United States
Mary Parks United States
Shiho Nakayama Japan
Cameron D. Thomas United States
Danny Soon Singapore
Junzo Watanabe Japan
Bhaskar Rege United States
Jun Miura Japan
S. Aubrey Stoch United States
Melvin Munsaka
Citations per year, relative to Melvin Munsaka Melvin Munsaka (= 1×) peers S. Aubrey Stoch

Countries citing papers authored by Melvin Munsaka

Since Specialization
Citations

This map shows the geographic impact of Melvin Munsaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin Munsaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin Munsaka more than expected).

Fields of papers citing papers by Melvin Munsaka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin Munsaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin Munsaka. The network helps show where Melvin Munsaka may publish in the future.

Co-authorship network of co-authors of Melvin Munsaka

This figure shows the co-authorship network connecting the top 25 collaborators of Melvin Munsaka. A scholar is included among the top collaborators of Melvin Munsaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melvin Munsaka. Melvin Munsaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Sulais, Eman Al, Édouard Louis, Bernd Bokemeyer, et al.. (2024). Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire. Journal of Crohn s and Colitis. 19(2). 2 indexed citations
2.
3.
Wang, William, et al.. (2021). Quantitative Drug Safety and Benefit-Risk Evaluation. 6 indexed citations
4.
Nilsson, Mary, Brenda Crowe, Greg Anglin, et al.. (2020). Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19. Statistics in Biopharmaceutical Research. 12(4). 498–505. 2 indexed citations
5.
Marcinak, John, Melvin Munsaka, Paul B. Watkins, Takashi Ohira, & Neila Smith. (2018). Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience. Drug Safety. 41(6). 625–640. 33 indexed citations
6.
Wang, William, et al.. (2017). On Quantitative Methods for Clinical Safety Monitoring in Drug Development. Statistics in Biopharmaceutical Research. 10(2). 85–97. 10 indexed citations
7.
Khalid, Javaria Mona, Laurent Peyrin‐Biroulet, Alessandro Armuzzi, et al.. (2016). Predictors of Non-response or Loss of Response to Tumour Necrosis Factor Antagonist Therapies in Inflammatory Bowel Disease. The American Journal of Gastroenterology. 111. S316–S316. 1 indexed citations
8.
Karim, Aziz, et al.. (2016). Effects of Food Intake on the Pharmacokinetics of Azilsartan Medoxomil and Chlorthalidone Alone and in Fixed‐Dose Combination in Healthy Adults. Clinical Pharmacology in Drug Development. 5(5). 393–398. 5 indexed citations
9.
White, William B., Richard E. Pratley, P. Fleck, et al.. (2013). Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 15(7). 668–673. 105 indexed citations
10.
Wang, Ying, George G. Nomikos, Aziz Karim, et al.. (2013). Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study. Clinical Pharmacology in Drug Development. 2(4). 298–309. 17 indexed citations
11.
Munsaka, Melvin, et al.. (2011). Using SAS® for Modeling and Simulation in Drug Development - A Review and Assessment of Some Available Tools.
12.
Karim, Aziz, Aziz Laurent, Melvin Munsaka, et al.. (2009). Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants. The Journal of Clinical Pharmacology. 49(10). 1210–1219. 34 indexed citations
13.
Manber, Rachel, A. John Rush, Michael E. Thase, et al.. (2003). The Effects of Psychotherapy, Nefazodone, and Their Combination on Subjective Assessment of Disturbed Sleep in Chronic Depression. SLEEP. 26(2). 130–136. 65 indexed citations
14.
Bialer, Meir, et al.. (1998). Criteria to Assess In Vivo Performance and Bioequivalence of Generic Controlled‐Release Formulations of Carbamazepine. Epilepsia. 39(5). 513–519. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Aubrey Stoch Breakdown of academic impact, for papers by Tine Laethem Breakdown of academic impact, for papers by Mary Parks Breakdown of academic impact, for papers by Shiho Nakayama Breakdown of academic impact, for papers by Cameron D. Thomas Breakdown of academic impact, for papers by Danny Soon Breakdown of academic impact, for papers by Junzo Watanabe Breakdown of academic impact, for papers by Bhaskar Rege Breakdown of academic impact, for papers by Jun Miura
Rankless by CCL
2026